Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic Academic Article uri icon

  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All


  • Herein we evaluate the impact of COVID-19 restrictions on antidepressant effectiveness of intravenous (IV) ketamine in adults with treatment-resistant depression (TRD). We conducted a case series analysis of adults with TRD (n = 267) who received four ketamine infusions at an outpatient clinic in Ontario, Canada, during COVID-19 restrictions (from March 2020 - February 2021; n = 107), compared to patients who received treatment in the previous year (March 2019 - February 2020; n = 160). Both groups experienced significant and comparable improvements in depressive symptoms, suicidal ideation, and anxiety with repeated ketamine infusions. Effectiveness of IV ketamine was not attenuated during the COVID-19 period.


  • Rosenblat, Joshua D
  • Lipsitz, Orly
  • Di Vincenzo, Joshua D
  • Rodrigues, Nelson B
  • Kratiuk, Kevin
  • Subramaniapillai, Mehala
  • Lee, Yena
  • Arekapudi, Anil K
  • Abrishami, Amir
  • Chau, Edmond H
  • Szpejda, Witold
  • Wong, Leslie
  • Mansur, Rodrigo B
  • McIntyre, Roger S

publication date

  • September 2021